Baebies partners with Medical Horizons to launch the SEEKER platform in Italy

Baebies Partners with Medical Horizons to Launch SEEKER Newborn Screening Platform in Italy

Florence, Italy, May 10, 2022 /PRNewswire/ — Baebies®, a growth-stage medical device company developing innovative products to enable early disease detection and multifunctional diagnostic tests for children and adults, in partnership with medical device provider Medical Horizons, announced today that newborns in Italy are being tested with the Baebies platform SEEKER®.

The Meyer Children’s Hospital Pharmacology, Clinical Chemistry and Newborn Screening Laboratory in Florence becomes the first laboratory in Italy to screen newborns for lysosomal storage disorders (LSD), including Pompe disease, mucopolysaccharidosis type I, Fabry and Gaucher on the SEEKER platform.

Powered by digital microfluidic technology, SEEKER is an FDA approved and CE marked newborn LSD screening platform. Its flexible, high-throughput laboratory solution provides newborn screening results in less than 3 hours for multiple LSDs from a single dried blood sample.

“Our continued expansion of digital microfluidic technology into new global markets represents exciting opportunities to screen more babies and save more lives,” he said. Vamsee Pamula, co-founder and CEO of Baebies. “We look forward to many more opportunities with Medical Horizons.”

The technology selection process at Meyer Children’s Hospital was led by Dr. Giancarlo la Marca, deputy head of the department of the Laboratory of Neonatal Exploration, Clinical Chemistry and Pharmacology. Dr. la Marca is a recognized global authority on newborn screening, working closely with the International Society for Neonatal Screening to advance the research and adoption of newborn screening around the world.

“There is no perfect solution for all newborn screening tests. It is important to use the best tool for each condition,” said Dr. Marca. “Using digital microfluidic technology to detect lysosomal storage disorders frees up our mass spectrometer for further testing and research.”

Other key criteria that contributed to the selection of the SEEKER platform were its compact size and ease of use.

Currently, LSD screening in newborns is not mandatory in Italy. However, an amendment to current newborn screening legislation could speed the inclusion of new conditions such as LSD on screening panels across the country.

“Our goal is to ensure that the labs we serve are prepared when screening tests become mandatory,” he said. Guido Osti, CEO of Medical Horizons. “The launch of SEEKER at this first location in Florence is an important step forward.”

About BabiesGuided by the vision that “everyone deserves a healthy start,” Babies performs millions of tests around the world each year to save lives and improve them. Baebies is a pioneer in digital microfluidics, which maximizes diagnostic performance from low volume samples. Based in Durham, North Carolinaits products are used in central laboratories and point-of-care around the world.

About Medical HorizonsMedical Horizons was created to identify medical innovation around the world, which had the potential to become innovative new products and then develop their commercialization with the most selected Italian sales network. Medical Horizons’ experience includes understanding the commercial interest that the innovative device will have for the Italian market to ensure that these products meet the perceived need of potential buyers.

Logo – https://mma.prnewswire.com/media/465102/Baebies_Inc_Logo.jpg

Share:

Facebook
Twitter
LinkedIn

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

On Key

Related Posts